Abstract: The present invention provides therapeutic and diagnostic methods and compositions for treating a human metastatic cancer. Specifically, the invention provides methods of treatment and methods for determining whether an individual suffering from a cancer is responding to an AXL decoy protein-based therapy, predicting responsiveness of an individual suffering from a cancer to treatment comprising an AXL decoy protein, and methods of selecting a therapy for an individual suffering from cancer.

Abstract: Provided herein are compositions and methods for the treatment of a triple-negative breast cancer, ovarian cancer and castration-resistant prostate cancer. Said compositions comprise CDK12/13 inhibitors.

Abstract: The present disclosure is directed to meditope-antibody covalent binding modalities that can be activated only after the meditope associates with a binding site on the meditope-enabled antibody. To this end, provided herein is a meditope engineered to contain a photoreactive functional group at one or more specific location(s) on the meditope so as not interfere with the specific noncovalent molecular interaction with the binding site on the meditope-enabled antibody, but still permits, and enhances, covalent bond formation. This methodology, with its speed, accuracy, consistency and simplicity has evident advantages for the development of antibody-drug conjugates.

Abstract: The present invention relates generally to compositions and methods comprising histidyl-tRNA synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to Jo-1 antibodies.

Abstract: The present invention relates generally to compositions and methods comprising histidyl-tRNA synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to Jo-1 antibodies.

Abstract: The present invention relates generally to compositions and methods comprising histidyl-tRNA synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to Jo-1 antibodies.

Abstract: The present invention relates generally to compositions and methods comprising histidyl-tRNA synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to Jo-1 antibodies.

Abstract: The present invention relates generally to compositions and methods comprising histidyl-tRNA synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to Jo-1 antibodies.

Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of Rho kinase for the treatment or prevention of disease.

Abstract: The present invention relates to compounds and methods useful as inhibitors of p38 kinase for the treatment or prevention and treatment of diseases such as inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, angiogenic disorders, infectious diseases, neurodegenerative diseases, and viral diseases.